Desorption

Perma-Fix Announces New Therma-Fix Gen³, Third Generation Vacuum Thermal Desorption System to Treat Problematic Waste Streams

Retrieved on: 
Friday, June 18, 2021
Physical sciences, LLW, Earth sciences, Low-level waste, Thermal desorption, Desorption, Natural sciences, Perma

Therma-Fix Gen3 heats low level waste (LLW) and mixed low-level waste (MLLW) to remove organics and recollects organics and mercury as condensate.

Key Points: 
  • Therma-Fix Gen3 heats low level waste (LLW) and mixed low-level waste (MLLW) to remove organics and recollects organics and mercury as condensate.
  • The electrically heated batch oven system has an operating range of up to 1,400 F and utilizes a tray system to permit discreet segregation of customer waste.
  • This first-in-kind system utilizes a unique vacuum thermal desorption technology and represents an important milestone for Perma-Fix as it expands the capacity of the system for a variety of problematic waste streams.
  • Drawing on Perma-Fixs many years of technological advancements and desorption-specific waste processing experience, the ThermafixGen3 system provides more efficient and cost-effective waste treatment for existing and future clients.

SAMDI Tech Provides 1+ Million Compounds Through WuXi Partnership for Drug Candidate Screening

Retrieved on: 
Tuesday, February 26, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Research, Science, Health sciences, Pharmaceutical sciences, Natural sciences, Pharmaceutics, Drug discovery, Clinical pharmacology, Pharmacognosy, High-throughput screening, Assay, Desorption

LabNetwork, a WuXi AppTec company, will facilitate the delivery of the compounds to SAMDI Tech from WuXis global network of providers.

Key Points: 
  • LabNetwork, a WuXi AppTec company, will facilitate the delivery of the compounds to SAMDI Tech from WuXis global network of providers.
  • SAMDI Tech simplifies and streamlines drug candidate screening using its proprietary high-throughput SAMDI (Self-Assembled Monolayer Desorption Ionization) assay.
  • The partnership will provide access to WuXis commercial collection of more than 300,000 compounds, further diversifying the number of compounds and compound class choices available through SAMDI Tech.
  • SAMDI Tech Inc. delivers better, faster and label-free assay development, high-throughput screening and peptide substrate discovery solutions for early-stage drug candidate selection.